The scientific focus adapted
to express the optimum potential
of your molecule

Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > Whole body glucose turnover

whole body glucose turnover

State-of-the-art technique for investigating and quantifying the effect of your compound on whole-body glucose metabolism in a context of type 2 diabetes.

key benefits

  • Sensitivity (15%) sufficient to detect a statistically significant impact of your compound on glucose metabolism: a lack of significant results in blood glucose assays does not imply your drug compound doesn’t improve glucose turnover.
  • Essential and robust data for your records: isotopic glucose enrichment provides unique insights into whole-body glucose metabolism (glucose turnover, glycolysis and glycogen synthesis).

description and parameters

Glucose turnover using radiolabeled tracers is invaluable for assessing whole body glucose metabolism in vivo.


  • Rat
  • Mouse

Parameters evaluated

  • Glucose fluxes
    • Glucose turnover (= hepatic glucose production)
    • Whole-body glycolysis rate
    • Whole-body glycogen synthesis
  • Glycemia
  • Glucose clearance rate

Add-on studies

  • Individual tissue glucose uptake assay to identify specific tissues targeted by your compound, and to identify unexpected adverse effects or additional tissue-specific benefits.
  • Euglycemic hyperinsulinemic clamp + 3H-glucose in the insulin-stimulated state to profile your compound’s efficacy on Insulin sensitivity
  • FFA turnover in basal conditions to complete your compound’s lipid profiling.

Fact sheet

Whole body glucose turnover


Andreelli F. et al, Endocrinology, 2006, 147: 2432-41.
Burcelin R. et al, Diabetes, 2000, 49: 1635-42.
Burcelin R. et al, Diabetes, 1999, 48: 16264-9.